兰卫医学
(301060)
| 流通市值：35.37亿 | | | 总市值：39.33亿 |
| 流通股本：3.60亿 | | | 总股本：4.01亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 759,388,284.42 | 350,884,969.11 | 1,742,181,004.45 | 1,320,029,736.34 |
| 营业收入 | 759,388,284.42 | 350,884,969.11 | 1,742,181,004.45 | 1,320,029,736.34 |
| 二、营业总成本 | 737,940,752 | 350,095,343.91 | 1,734,032,450.01 | 1,298,282,175.55 |
| 营业成本 | 588,178,035.39 | 280,874,494.68 | 1,357,465,426.08 | 1,042,867,677.7 |
| 税金及附加 | 2,852,029.49 | 1,412,361.62 | 6,565,496.97 | 5,124,977.25 |
| 销售费用 | 38,854,498.53 | 18,263,941.75 | 88,946,942.94 | 57,780,785.6 |
| 管理费用 | 81,307,833.46 | 37,305,755.7 | 215,302,090.53 | 142,639,218.64 |
| 研发费用 | 24,609,239.63 | 11,490,853.98 | 59,972,581.74 | 44,916,908.61 |
| 财务费用 | 2,139,115.5 | 747,936.18 | 5,779,911.75 | 4,952,607.75 |
| 其中:利息费用 | 3,585,277.82 | 3,291,839.37 | 10,808,964.34 | 8,047,621.21 |
| 其中:利息收入 | 1,733,989.57 | 2,753,571.5 | 6,246,244.51 | 3,988,277.61 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 51,715.73 | 51,715.73 | - | - |
| 加:投资收益 | -1,822,039.79 | 298,518.6 | 4,379,506.45 | 4,523,572.46 |
| 资产处置收益 | -31,469.29 | 55,506.81 | 5,667,528.69 | -188,506.04 |
| 资产减值损失(新) | -6,495,306.77 | -7,487,033.3 | -79,018,069.7 | -68,176,621.46 |
| 信用减值损失(新) | -12,174,034.53 | -2,345,983.23 | -24,388,185.28 | -30,771,031.56 |
| 其他收益 | 4,585,302.9 | 1,964,123.69 | 15,902,748.65 | 11,996,181 |
| 四、营业利润 | 5,561,700.67 | -6,673,526.5 | -69,307,916.75 | -60,868,844.81 |
| 加:营业外收入 | 732,026.93 | 41,095.18 | 1,513,479.16 | 1,176,151.87 |
| 减:营业外支出 | 2,517,386.44 | 455,104.06 | 35,021,601.71 | 4,980,552.14 |
| 五、利润总额 | 3,776,341.16 | -7,087,535.38 | -102,816,039.3 | -64,673,245.08 |
| 减:所得税费用 | 7,583,042.18 | 1,338,717.6 | -4,225,861.21 | -11,494,048.52 |
| 六、净利润 | -3,806,701.02 | -8,426,252.98 | -98,590,178.09 | -53,179,196.56 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -3,806,701.02 | -8,426,252.98 | -98,590,178.09 | -53,179,196.56 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -5,783,174.11 | -8,080,860.79 | -109,436,220.8 | -40,583,766.31 |
| 少数股东损益 | 1,976,473.09 | -345,392.19 | 10,846,042.71 | -12,595,430.25 |
| 扣除非经常损益后的净利润 | -7,643,223.39 | -10,874,027.14 | -109,080,713.7 | -49,543,457.56 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.01 | -0.02 | -0.27 | -0.1 |
| (二)稀释每股收益 | -0.01 | -0.02 | -0.27 | -0.1 |
| 九、综合收益总额 | -3,806,701.02 | -8,426,252.98 | -98,590,178.09 | -53,179,196.56 |
| 归属于母公司股东的综合收益总额 | -5,783,174.11 | -8,080,860.79 | -109,436,220.8 | -40,583,766.31 |
| 归属于少数股东的综合收益总额 | 1,976,473.09 | -345,392.19 | 10,846,042.71 | -12,595,430.25 |
| 公告日期 | 2025-08-26 | 2025-04-28 | 2025-04-28 | 2024-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |